Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J et al
Safety considerations hinge on formulation quality, sourcing practices, sterile compounding standards, and appropriate clinical oversight
the key is choosing activities you enjoy enough to continue after treatment ends
The Phase 2b OPTIONS trial 536 obese subjects, randomized to receive 0.25, 0.5, or 1 mg/day oral AOD-9604 or placebo over 24 weeks failed to demonstrate statistically significant weight loss at any dose tested
Discuss with your GP or endocrinologist before starting Ozempic to ensure individualised assessment of suitability, monitoring requirements, and potential medication adjustments
And to really hedge your bets, make sure you have enough glutathione precursors in your routine